Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Setbacks and promises for drugs against Alzheimer's disease: As pharmaceutical companies are retreating from drug development for Alzheimer's, new approaches are being tested in academia and biotech companies.

Literature DB >> 30150324

Setbacks and promises for drugs against Alzheimer's disease: As pharmaceutical companies are retreating from drug development for Alzheimer's, new approaches are being tested in academia and biotech companies.

Andrea Rinaldi¹.
1. Cagliari, Italy.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2018 PMID： 30150324 PMCID： PMC6123640 DOI： 10.15252/embr.201846714

Source DB: PubMed Journal: EMBO Rep ISSN： 1469-221X Impact factor: 8.807

× No keyword cloud information.

10 in total

1. Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.

Authors: Alireza Atri; Lutz Frölich; Clive Ballard; Pierre N Tariot; José Luis Molinuevo; Neli Boneva; Kristian Windfeld; Lars L Raket; Jeffrey L Cummings
Journal: JAMA Date: 2018-01-09 Impact factor: 56.272

Review 2. Neuroregeneration versus neurodegeneration: toward a paradigm shift in Alzheimer's disease drug discovery.

Authors: Elisa Uliassi; Annachiara Gandini; Rosaria Carmela Perone; Maria Laura Bolognesi
Journal: Future Med Chem Date: 2017-06-20 Impact factor: 3.808

3. Challenges, solutions, and recommendations for Alzheimer's disease combination therapy.

Authors: James A Hendrix; Randall J Bateman; H Robert Brashear; Cynthia Duggan; Maria C Carrillo; Lisa J Bain; Ronald DeMattos; Russell G Katz; Susanne Ostrowitzki; Eric Siemers; Reisa Sperling; Ottavio V Vitolo
Journal: Alzheimers Dement Date: 2016-03-24 Impact factor: 21.566

4. Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease.

Authors: Lawrence S Honig; Bruno Vellas; Michael Woodward; Mercè Boada; Roger Bullock; Michael Borrie; Klaus Hager; Niels Andreasen; Elio Scarpini; Hong Liu-Seifert; Michael Case; Robert A Dean; Ann Hake; Karen Sundell; Vicki Poole Hoffmann; Christopher Carlson; Rashna Khanna; Mark Mintun; Ronald DeMattos; Katherine J Selzler; Eric Siemers
Journal: N Engl J Med Date: 2018-01-25 Impact factor: 91.245

5. The Transcription Factor Sp3 Cooperates with HDAC2 to Regulate Synaptic Function and Plasticity in Neurons.

Authors: Hidekuni Yamakawa; Jemmie Cheng; Jay Penney; Fan Gao; Richard Rueda; Jun Wang; Satoko Yamakawa; Oleg Kritskiy; Elizabeta Gjoneska; Li-Huei Tsai
Journal: Cell Rep Date: 2017-08-08 Impact factor: 9.423

Review 6. VDAC1, mitochondrial dysfunction, and Alzheimer's disease.

Authors: Varda Shoshan-Barmatz; Edna Nahon-Crystal; Anna Shteinfer-Kuzmine; Rajeev Gupta
Journal: Pharmacol Res Date: 2018-03-15 Impact factor: 7.658

7. Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation.

Authors: Fan Liao; Aimin Li; Monica Xiong; Nga Bien-Ly; Hong Jiang; Yin Zhang; Mary Beth Finn; Rosa Hoyle; Jennifer Keyser; Katheryn B Lefton; Grace O Robinson; Javier Remolina Serrano; Adam P Silverman; Jing L Guo; Jennifer Getz; Kirk Henne; Cheryl Eg Leyns; Gilbert Gallardo; Jason D Ulrich; Patrick M Sullivan; Eli Paul Lerner; Eloise Hudry; Zachary K Sweeney; Mark S Dennis; Bradley T Hyman; Ryan J Watts; David M Holtzman
Journal: J Clin Invest Date: 2018-03-30 Impact factor: 14.808

8. The molecular basis of Alzheimer's plaques.

Authors: Sabrina Pospich; Stefan Raunser
Journal: Science Date: 2017-10-06 Impact factor: 47.728

Review 9. Alzheimer's disease drug development pipeline: 2017.

Authors: Jeffrey Cummings; Garam Lee; Travis Mortsdorf; Aaron Ritter; Kate Zhong
Journal: Alzheimers Dement (N Y) Date: 2017-05-24

Review 10. The amyloid hypothesis of Alzheimer's disease at 25 years.

Authors: Dennis J Selkoe; John Hardy
Journal: EMBO Mol Med Date: 2016-06-01 Impact factor: 12.137